Zhu Q, Yang J, Shi L, Zhang J, Zhang P, Li J
Front Immunol. 2025; 16:1534389.
PMID: 39958329
PMC: 11825825.
DOI: 10.3389/fimmu.2025.1534389.
Corsetti G, Romano C, Pasini E, Scarabelli T, Chen-Scarabelli C, Dioguardi F
Nutrients. 2023; 15(10).
PMID: 37242170
PMC: 10222879.
DOI: 10.3390/nu15102287.
Ildefonso G, Metzig M, Hoffmann A, Harris L, Lopez C
Biophys J. 2023; 122(5):817-834.
PMID: 36710493
PMC: 10027451.
DOI: 10.1016/j.bpj.2023.01.035.
Yin H, Guo X, Chen Y, Zeng Y, Mo X, Hong S
J Clin Invest. 2022; 132(4).
PMID: 34990405
PMC: 8843707.
DOI: 10.1172/JCI152297.
Ang R, Chan M, Legarda D, Sundberg J, Sun S, Gillespie V
Proc Natl Acad Sci U S A. 2021; 118(50).
PMID: 34887354
PMC: 8685717.
DOI: 10.1073/pnas.2001602118.
TNFR1-d2 carrying the p.(Thr79Met) pathogenic variant is a potential novel actor of TNFα/TNFR1 signalling regulation in the pathophysiology of TRAPS.
Rittore C, Mechin D, Sanchez E, Marineche L, Ea V, Soler S
Sci Rep. 2021; 11(1):4172.
PMID: 33603056
PMC: 7893027.
DOI: 10.1038/s41598-021-83539-9.
RIP1 promotes proliferation through G2/M checkpoint progression and mediates cisplatin-induced apoptosis and necroptosis in human ovarian cancer cells.
Zheng X, Yang J, Wang Y, Li Q, Song Y, Su M
Acta Pharmacol Sin. 2020; 41(9):1223-1233.
PMID: 32242118
PMC: 7608477.
DOI: 10.1038/s41401-019-0340-7.
Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL).
Xu X, Kalac M, Markson M, Chan M, Brody J, Bhagat G
Cell Death Dis. 2020; 11(2):94.
PMID: 32024820
PMC: 7002447.
DOI: 10.1038/s41419-020-2294-6.
Receptor‑interacting serine/threonine‑protein kinase 1 promotes the progress and lymph metastasis of gallbladder cancer.
Zhu G, Du Q, Chen X, Wang X, Tang N, She F
Oncol Rep. 2019; 42(6):2435-2449.
PMID: 31545498
PMC: 6844244.
DOI: 10.3892/or.2019.7331.
Ripoptocide - A Spark for Inflammation.
Ang R, Chan M, Ting A
Front Cell Dev Biol. 2019; 7:163.
PMID: 31457011
PMC: 6700212.
DOI: 10.3389/fcell.2019.00163.
Tumor necrosis factor-driven cell death in donor organ as a barrier to immunological tolerance.
Ang R, Ting A
Curr Opin Organ Transplant. 2018; 24(1):12-19.
PMID: 30507704
PMC: 6597188.
DOI: 10.1097/MOT.0000000000000599.
Selective Modulation of TNF-TNFRs Signaling: Insights for Multiple Sclerosis Treatment.
Pegoretti V, Baron W, Laman J, Eisel U
Front Immunol. 2018; 9:925.
PMID: 29760711
PMC: 5936749.
DOI: 10.3389/fimmu.2018.00925.
Mind Bomb Regulates Cell Death during TNF Signaling by Suppressing RIPK1's Cytotoxic Potential.
Feltham R, Jamal K, Tenev T, Liccardi G, Jaco I, Domingues C
Cell Rep. 2018; 23(2):470-484.
PMID: 29642005
PMC: 5912950.
DOI: 10.1016/j.celrep.2018.03.054.
MK2 Phosphorylates RIPK1 to Prevent TNF-Induced Cell Death.
Jaco I, Annibaldi A, Lalaoui N, Wilson R, Tenev T, Laurien L
Mol Cell. 2017; 66(5):698-710.e5.
PMID: 28506461
PMC: 5459754.
DOI: 10.1016/j.molcel.2017.05.003.
Knockdown of miR-182 promotes apoptosis via regulating RIP1 deubiquitination in TNF-α-treated triple-negative breast cancer cells.
Wo L, Lu D, Gu X
Tumour Biol. 2016; 37(10):13733-13742.
PMID: 27476169
DOI: 10.1007/s13277-016-5174-z.
CYLD Proteolysis Protects Macrophages from TNF-Mediated Auto-necroptosis Induced by LPS and Licensed by Type I IFN.
Legarda D, Justus S, Ang R, Rikhi N, Li W, Moran T
Cell Rep. 2016; 15(11):2449-61.
PMID: 27264187
PMC: 4909532.
DOI: 10.1016/j.celrep.2016.05.032.
A novel function of RIP1 in postnatal development and immune homeostasis by protecting against RIP3-dependent necroptosis and FADD-mediated apoptosis.
Dowling J, Nair A, Zhang J
Front Cell Dev Biol. 2015; 3:12.
PMID: 25767797
PMC: 4341114.
DOI: 10.3389/fcell.2015.00012.
CYLD deubiquitinates RIP1 in the TNFα-induced necrosome to facilitate kinase activation and programmed necrosis.
Moquin D, McQuade T, Chan F
PLoS One. 2013; 8(10):e76841.
PMID: 24098568
PMC: 3788787.
DOI: 10.1371/journal.pone.0076841.
RIP1 potentiates BPDE-induced transformation in human bronchial epithelial cells through catalase-mediated suppression of excessive reactive oxygen species.
Wang Q, Chen W, Xu X, Li B, He W, Padilla M
Carcinogenesis. 2013; 34(9):2119-28.
PMID: 23633517
PMC: 3765041.
DOI: 10.1093/carcin/bgt143.
Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.
Salzmann S, Seher A, Trebing J, Weisenberger D, Rosenthal A, Siegmund D
J Biol Chem. 2013; 288(19):13455-66.
PMID: 23532848
PMC: 3650383.
DOI: 10.1074/jbc.M112.435917.